CD8A and neoplasm: Supporting this, Lapieza et al. provided strong evidence that the intravenous administration of BCG in mice activates robust NK and CD8+ T cell responses, which significantly enhances anti-tumour immunity in the lungs and effectively overcomes resistance to existing immunotherapies.